Physician profile
Ashley E Fallucca
NPI 1245531979
$2,594.99
in general payments reported to CMS, 2019-2025
31 companies · $726 in 2025
The $726 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $285 · 2023: $507 · 2024: $438 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $517.79 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $416.37 | 2021-2025 | |
| Novo Nordisk INC | $395.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $258.41 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $125.97 | 2021-2025 | Evenity, Prolia |
| Kowa Pharmaceuticals America, INC. | $79.41 | 2021-2025 | Zoryve, Livalo |
| Pfizer INC. | $79.14 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $68.42 | 2021-2022 | |
| Boston Scientific Corporation | $61.47 | 2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $55.77 | 2023 | Quviviq |
| Amarin Pharma, INC. | $49.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.92 | 2021-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $48.67 | 2022-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $32.66 | 2024-2025 | Voquezna |
| Ibsa Pharma INC. | $30.79 | 2023-2025 | Tirosint, Flector, Licart |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.70 | 2022 | |
| Dexcom, INC. | $29.53 | 2022-2025 | Dexcom G6 Transmitter |
| Neos Therapeutics, LP | $28.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.00 | 2024 | |
| Astellas Pharma US INC | $21.33 | 2024 | Veozah |
| Emd Serono, INC. | $21.07 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.66 | 2021 | |
| Mannkind Corporation | $17.99 | 2022 | |
| Merck Sharp & Dohme LLC | $17.00 | 2024 | Capvaxive, Gardasil 9, Proquad |
| Amneal Pharmaceuticals LLC | $16.80 | 2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.51 | 2021 | |
| Clarus Therapeutics INC. | $13.98 | 2021 | |
| Glaxosmithkline, LLC. | $13.73 | 2023 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $13.67 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Fallucca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.